Once-daily oral berotralstat for long-term prophylaxis of hereditary angioedema: The open-label extension of the APeX-2 randomized trial

Authors

Sorena Kiani-Alikhan, Royal Free London NHS Foundation Trust
H James Wedner, Washington University School of Medicine in St. Louis
et al.

Journal

Journal of Allergy and Clinical Immunology: In Practice

Publication Date

3-1-2024

Volume

12

Issue

3

First Page

733

Last Page

743.e10

Document Type

Open Access Publication

DOI

10.1016/j.jaip.2023.12.019

Rights and Permissions

Kiani-Alikhan S, Gower R, Craig T, Wedner HJ, Kinaciyan T, Aygören-Pürsün E, Banerji A, Bernstein JA, Anderson J, Collis P, Johnston DT, Desai B, Tomita D, Gagnon R, Tachdjian R, Soteres DF, Farkas H, Caballero T, McNeil D, Jacobs J, Lumry WR; APeX-2 investigators. Once-Daily Oral Berotralstat for Long-Term Prophylaxis of Hereditary Angioedema: The Open-Label Extension of the APeX-2 Randomized Trial. J Allergy Clin Immunol Pract. 2024 Mar;12(3):733-743.e10. doi: 10.1016/j.jaip.2023.12.019. Copyright 2024 The Authors. Published by Elsevier Inc. on behalf of the American Academy of Allergy, Asthma & Immunology. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/bync-nd/4.0/).

Recommended Citation

Kiani-Alikhan, Sorena; Wedner, H James; and et al., "Once-daily oral berotralstat for long-term prophylaxis of hereditary angioedema: The open-label extension of the APeX-2 randomized trial." Journal of Allergy and Clinical Immunology: In Practice. 12, 3. 733 - 743.e10. (2024).
https://digitalcommons.wustl.edu/oa_4/4513

Department

ICTS (Institute of Clinical and Translational Sciences)